Johnson & Johnson has signed a deal to use Halozyme Therapeutics' drug delivery platform in its own R&D efforts, agreeing to pay as much as $581 million for the privilege.
In biotech, you don't raise money when you need it. You raise cash when you can. And right now, Juno Therapeutics is bundling cash in bulk.
After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.
The FDA again rejected Pozen's pair of treatments designed to help patients deal with cardiovascular disease, citing the same third-party manufacturing issues that tanked the last application. Pozen claims the supplier has since rectified those concerns but that the agency has been less than cooperative in the process.
Auspex Pharmaceuticals' treatment for a movement disorder tied to Huntington's disease met its main goal in a late-stage study, the company said, clearing the way for a 2015 FDA filing.
Google Ventures is betting more and more on life sciences startups each year, and the well-funded financier tells The Wall Street Journal that's not going to change in the new year.
The biopharma industry's headlong rush into cancer drug research has created a fierce competition for top talent in the field, as underscored by Gilead's decision to raid the senior ranks of Genentech for an R&D leader who's being charged with the lead role in oncology. Gilead has recruited Philippe Bishop, who once headed the Avastin program, to take the lead as senior vice president of hematology and oncology therapeutics.
A few weeks ago Belgium's Galapagos touted some early-stage data on GLPG1205, a new drug for inflammatory bowel diseases which it discovered under a $1 billion-plus partnership deal inked with J&J back in 2007. But today J&J bowed out of the pact for the entire GPR84 program, an effort that includes GLPG1205 and its backup compound GLPG2196.
Cyclacel Pharmaceuticals' in-development leukemia drug has little chance of meeting its primary goal in a late-stage study, independent advisers said. But, because the treatment isn't leading to serious side effects, the company is keeping the trial running.
The FDA signed off on a once-a-month version of Novartis' Signifor designed to treat acromegaly, a rare growth hormone disorder that can lead to disfigurement and death.
Patrick Soon-Shiong, billionaire physician and biotech entrepreneur, wants in on the hottest field in oncology, forming a joint venture with Sorrento Therapeutics to develop therapies that harness the body's immune system to fight cancer.
Partners Roche and Exelixis are making their case to regulators with a melanoma-treating combination therapy, filing an FDA application for the fast-tracked treatment as they await European clearance.
Today, Vertex announced that David Altshuler, the deputy director and chief academic officer of the legendary Broad Institute, will be the Boston biotech's new CSO, taking the place of the pioneering Peter Mueller.
Taking an early look at data from an ongoing study of Sophiris' lead drug, independent advisers say the prostate-shrinking therapy didn't meet its predefined threshold for efficacy, casting a shadow over the biotech's only clinical asset.
Novartis Venture Fund has stepped in to take the lead on a $34 million venture round for Redwood City, CA-based upstart Annexon Bioscience, which believes it has the inside track on a new treatment for Huntington's disease.
Pfizer's business development team is on a spending spree. Today the pharma giant said it is partnering with Miami-based Opko Health on a Phase III long acting growth hormone, paying $295 million upfront and promising up to $275 million more on regulatory milestones.
A little more than a year ago Tony Coles signed off on a deal to sell Onyx to Amgen for $10.4 billion, and carved off a $58 million-plus slice of that for himself in the process. But rather than sail off into the sunset with a great reputation and a pile of money, he's headed back to work. This morning Coles pulled back the covers on the new biotech he's building, and once again, he's thinking big as he takes the helm.
Jazz Pharmaceuticals has kicked off a rolling FDA submission for defibrotide, a rare disease treatment acquired in its $1 billion buyout of Gentium.
Moving on from the slow demise of its Merck KGaA-partnered cancer vaccine, Seattle's Oncothyreon has bought out co-developer Array BioPharma, acquiring exclusive rights to the pair's early-stage breast cancer candidate.